CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

Stock Information for Cytodyn Inc

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cytodyn Inc

December 2024 Letter to Shareholders
CytoDyn Appoints Richard Pestell, M.D., Ph.D. as Lead Consultant in Oncology
CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial
CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology; Announces Follow-Up Inflammation Studies with SMC Laboratories
CytoDyn Appoints Dr. Max Lataillade as Senior Vice President and Head of Clinical Development
CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free Viral Control in Infant Rhesus Macaques
CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial
CytoDyn Announces Preliminary Findings in Study with SMC Laboratories

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.